Nutrition21 CEO Michael Zeher said after the study results were in: "The results of this study expand the CLINICAL benefits of Chromax Chromium Picolinate and open the door for a new line of product applications covered by our expanding patent portfolio. This study is another example of the breakthrough CLINICAL research supported by Nutrition21". As investors we'll have to watch and see how this news shakes out!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.